A Validated Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Aliskiren Hemifumarate and Amlodipine Besylate in Pharmaceutical Dosage Form

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Parameters</td><td align="center">Aliskiren</td><td align="center">Amlodipine</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Retention time (min)</td><td align="center">3.98</td><td align="center">5.14</td></tr><tr><td align="left">USP plate count</td><td align="center">3545</td><td align="center">4743</td></tr><tr><td align="left">USP tailing </td><td align="center">1.33</td><td align="center">1.25</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Chromatography Research International

tab2

Table 2

Table 2: A Validated Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Aliskiren Hemifumarate and Amlodipine Besylate in Pharmaceutical Dosage Form 

Table 2 | A Validated Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Aliskiren Hemifumarate and Amlodipine Besylate in Pharmaceutical Dosage Form 